References

Cure Arthritis Naturally

Beat Arthritis Naturally

Get Instant Access

Anderson PJ (2005) Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 34(5 Suppl 1):19-22 Baert F, Noman M, Vermeire S, et al. (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348:601 -608 Baert F, Vermeire S, Noman M, et al. (2004) Management of ulcerative colitis and Crohn's disease. Acta Clin Belg 59:304-314 Barthel HR, Gille T, Halbsguth A, Kramer M (2005) Successful treatment with adalimumab in infliximab-resistant Crohn's disease. J Gastroenterol Hepatol 20:1464-1465 Bayless T, Talamini M, Kaufman H, et al. (2006) Digestive disease library: Colon & rectum, Crohn's disease. Available at: http://hopkins-gi.nts.jhu.edu/pages/latin/templates/ index.cfm?pg=disease1&organ=6&disease=21&lang_id= 1. Accessed April 17, 2006 Braegger CP, Nicholls S, Murch SH, et al. (1992) Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 339:89-91 Buhner S, Buning C, Genschel J, et al. (2006) Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation? Gut 55:342-347

Calenda KA, Schornagel IL, Sadeghi-Nejad A, Grand RJ (2005) Effect of recombinant growth hormone treatment on children with Crohn's disease and short stature: a pilot study. Inflamm Bowel Dis 11:435-441 Catrina AI, Trollmo C, af Klint E, et al. (2005) Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 52:61-72 Colombel JF, Sandborn WJ, Rutgeerts P, et al. (2006) Adalimu-mab induces and maintains clinical response and remission in patients with active Crohn's disease: results of the CHARM trial [abstract 686d]. Presented at Digestive Disease Week 2006, Los Angeles, California, May 23, 2006 Cucchiara S, Romeo E, Viola F, et al. (2006) Infliximab as a first choice therapy in children with newly diagnosed Crohn's disease (CD) promotes long-term sustained remission and alters the course of the disease [abstract 56]. Presented at Digestive Disease Week 2006, Los Angeles, California, May 21, 2006

Dieckgraefe BK, Korzenik JR (2002) Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet 360:1478-1480 Dignass A, Targan S, Salzberg B, et al. (2004) Visilizumab, a humanized anti CD3 monoclonal antibody is active in the treatment of severe steroid refractory ulcerative colitis: preliminary results of a phase I-II study. Gut 52(Suppl VI):A54 Feagan BG, Greenberg G, Wild G, et al. (2003) Efficacy and safety of a humanized a4ß7 antibody in active Crohn's disease (CD). Gastroenterology 124(Suppl 1):A25 (Abstract 178) Feagan BG, Greenberg GR, Wild G, et al. (2005) Treatment of ulcerative colitis with a humanized antibody to the a4ß7 integrin. N Engl J Med 352:2499-2507 Fossati G, Nesbitt AM (2005a) Effect of the anti-TNF agents, adalimumab, etanercept, infliximab, and certolizumab PEGOL (CDP870) on the induction of apoptosis in activated peripheral blood lymphocytes and monocytes. Am J Gastroenterol 100:S287 Fossati G, Nesbitt AM (2005b) In vitro complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by the anti-TNF agents adalimumab, etanercept, infliximab, and certolizumab pegol (CDP870). Am J Gastroenterol 100:S287 Ghosh S, Goldin E, Gordon FH, et al. (2003) Natalizumab for active Crohn's disease. N Engl J Med 348:24-32 Gordon FH, Lai CS, Hamilton MI, et al. (2001) A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 121:268-274 Granneman RG, Zhang Y, Noetersheuser PA, et al. (2003) Phar-macokinetic/pharmacodynamic (PK/PD) relationships of adalimumab (Humira™, Abbott) in rheumatoid arthritis patients during Phase II/III clinical trials [abstract]. Arthritis Rheum 48(Suppl):S140 (Poster 256) Hanauer SB, Feagan BG, Lichtenstein GR, et al. (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 359:1541 -1549 Hanauer SB, Present DH (2003) The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Dis 3:81-92

Hanauer SB, Sandborn WJ, Rutgeerts P, et al. (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimu-mab) in Crohn's disease: the CLASSIC-I Trial. Gastroenter-ology 130:323-333 Hommes DW, Mikhajlova TL, Stoinov S, et al. (2006) Fontoli-zumab, a humanized anti-interferon-gamma antibody, demonstrates safety and potential clinical activity in patients with moderate-to-severe Crohn's disease. Gut 0: gut.2005.079392v1 [Epub ahead of print] Hugot JP, Chamailard M, Zouali H, et al. (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411:599 -603 Humira [prescribing information] (2005) Abbott Laboratories, North Chicago, IL Hyams J, Crandall W, Kugathasan S, et al. (2006) Maintenance therapy with infliximab every 8 weeks is superior to every 12 weeks in maintaining response and remission in pediat-ric patients with moderately to severely active Crohn's disease [abstract 57]. Presented at Digestive Disease Week 2006, Los Angeles, California, May 21, 2006

Ito H, Takazoe M, Fukuda Y, et al. (2004) A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126: 989-996

Jarnerot G, Hertevig E, Friis-Liby I, et al. (2005) Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroen-terology 128:1805-1811 Jerne NK (1974) Towards a network theory of the immune system. Ann d'Immunologie 125C:373-389 Kobayashi KS, Chamaillard M, Ogura Y, et al. (2005) Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307:731-734 Korzenik JR, Podolsky DK (2006) Evolving knowledge and therapy of inflammatory bowel disease. Nat Rev Drug Dis-cov 5:197-209

Korzenik JR, Dieckgraefe BK, Valentine JF, et al., for the Sar-gramostim in Crohn's Disease Study Group (2005) Sargra-mostim for active Crohn's disease. N Engl J Med 352:2193 -2201

Lakatos PL, Fischer S, Lakatos L, et al. (2006) Current concept on the pathogenesis of inflammatory bowel disease - crosstalk between genetic and microbial factors: pathogenic bacteria and altered bacterial sensing or changes in mucosal integrity take "toll"? World J Gastroenterol 12:1829-1841 Maini RN, Breedveld FC, Kalden JR, et al. (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552-1563 Mannon PJ, Fuss IJ, Mayer L, et al; Anti-IL-12 Crohn's Disease Study Group (2004) Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 351:2069-2079 Miner P, Wedel M, Bane B, et al. (2004) An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in chronic intermitting pouchitis. Aliment Pharmacol Ther 19:281 - 286 Mitoma H, Horiuchi T, Hatta N, et al. (2005) Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-[945]. Gastroenterology 128:376-392 Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT (1993) Location of tumour necrosis factor alpha by immu-nohistochemistry in chronic inflammatory bowel disease. Gut 34:1705-1709 Murch SH, Lamkin VA, Savage MO, et al. (1991) Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 32:913-917 Musch E, Andus R, Malek M (2002) Induction and maintenance of clinical remission by interferon beta in patients with steroid-refractory active ulcerative colitis - an open long-term pilot trial. Aliment Pharmacol Ther 16:12331239

Nayar M, Rhodes JM (2004) Management of inflammatory bowel disease. Postgrad Med J 80:206-213 Nikolaus S, Rutgeerts P, Fedorak R, et al. (2003) Interferon beta-1a in ulcerative colitis: a placebo controlled, randomized, dose escalating study. Gut 52:1286-1290 Noble C, Nimmo E, Gaya D, et al. (2006) Novel susceptibility genes in inflammatory bowel disease. World J Gastroenterol 12:1991-1999

Ogura Y, Bonen DK, Inohara N, et al. (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411:603 - 606 Papadakis KA, Shaye OA, Vasiliauskas EA, et al. (2005) Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 100:75-79 Peltekova VD, Wintle RF, Rubin LA, et al. (2004) Functional variants of OCTN cation transporter genes are associated with Crohn's disease. Nat Genet 5:800-808 Reinisch W, Hommes DW, Van Assche G, et al. (2006) A dose-escalating, placebo-controlled, double-blind, single-dose and multi-dose, safety and tolerability study of fontolizu-mab, a humanized anti-interferon-gamma antibody, in patients with moderate-to-severe Crohn's disease. Gut. E-pub ahead of print. doi:10.1136/gut.2005.079434 Remicade (infliximab) prescribing information (2006) Cento-

cor, Inc. Malvern, PA, March, 2006 Rutgeerts P (2002) Current dilemmas in the management of inflammatory bowel disease. Eur J Surg Suppl (587):58-61 Rutgeerts P, Feagan BG, Lichtenstein GR, et al. (2004a) Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126:402413

Rutgeerts P, Fedorak RN, Rachmilevich D, et al., for the Oner-cept Study Group (2004b) Onercept (recombinant human p55 tumour necrosis factor receptor) treatment in patients with active Crohn's disease: randomized, placebo-controlled, dose-finding phase II study (abstract). Gut 53(Suppl VI):A47

Rutgeerts P, Sandborn WJ, Feagan BG, et al. (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353:2462-2476 Sandborn WJ, Hanauer SB, Katz S, et al. (2001) Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121:1088-1094 Sandborn WJ, Hanauer S, Loftus EV Jr, et al. (2004a) An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 99:1984-1989

Sandborn WJ, Feagan BG, Radford-Smith G, et al. (2004b) CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double-blind, placebo-controlled trial. Gut 53:1485-1493 Sandborn W, Hanauer S, Lukas M, et al. (2005a) Induction and maintenance of clinical remission and response in subjects with Crohn's disease treated during a 6-month open-label period with fully human anti-TNF- monoclonal antibody adalimumab (Humira®). Gastroenterology 128(4 Suppl 2):A-111 (presentation 723) Sandborn WJ, Hanauer S, Enns R, et al. (2005b) Maintenance of remission over 1 year in patients with active Crohn's disease treated with adalimumab: results of CLASSIC II, a blinded, placebo-controlled study. Gut 54(Suppl VII):A81 - 2 (oral presentation OP-G-353)

Sandborn WJ, Hanauer S, Lukas M, et al. (2005c) Clinical remission and response in patients with Crohn's disease treated with open-label for 1 year with fully human anti-TNF-a monoclonal antibody adalimumab. Gut 54(Suppl VII):A18 (oral presentation OP-G-78) Sandborn WJ, Colombel JF, Enns R, et al., for the International EfficacyofNatalizumab as Active Crohn's TherapyENACT-1 Trial Group and the Evaluation of Natalizumab as Continuous Therapy ENACT-2 Trial Group (2005d) Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353:1912-1925 Sandborn WJ, Feagan BG, Stoinov S, et al. (2006) Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26-week, placebo-controlled phase III study (PRECiSE 1). Presented at Digestive Disease Week 2006, Los Angeles, California, May 23, 2006 Sands BE, Anderson FH, Bernstein CN, et al. (2004) Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350:876-885 Scallon BJ, Moore MA, Trinh H, et al. (1995) Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7:251 -259 Schmidt C, Giese T, Ludwig B, Mueller-Molaian I, et al. (2005) Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcera-tive colitis. Inflamm Bowel Dis 11:16-23 Schreiber S (2005) Certolizumab pegol, a humanised anti-tnf pegylated fab' fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn's disease: a phase III study (PRECiSE). Presented at the 13th United European Gastroenterology Week, Copenhagen, Denmark, October 18, 2005 Schreiber S (2006) Slipping the barrier: how variants in CARD15 could alter permeability of the intestinal wall and population health. Gut 55:308-309 Schreiber S, Rutgeerts P, Fedorak RN, et al.; CDP870 Crohn's Disease Study Group (2005) A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129:807-818 Shen C, Assche GV, Colpaert S, et al. (2005) Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 21:251-258 Slonim AE, Bulone L, Damore MB, et al. (2000) A preliminary study of growth hormone therapy for Crohn's disease. N Engl J Med 342:1633 - 1637 Stallmach A, Giese T, Schmidt C, et al. (2004) Severe anaphy-lactic reaction to infliximab: successful treatment with ada-limumab - report of a case. Eur J Gastroenterol Hepatol 16:627-630

Stoll M, Corneliussen B, Costello CM, et al. (2004) Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet 36:476-480 Targan SR, Hanauer SB, van Deventer SJ, et al., for the Crohn's Disease cA2 Study Group (1997) A short-term study of chi-meric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 337:1029 -1035 Van Assche G, Vermeire S, Rutgeerts P (2005) Medical treatment of inflammatory bowel diseases. Curr Opin Gastroenterol 21:443-447 van den Brande JM, Braat H, van den Brink GR, et al. (2003) Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124:1774-1785 van Deventer SJ (2003) New biological therapies in inflammatory bowel disease. Best Pract Res Clin Gastroenterol 17: 119-130

van Deventer SJ, Tami JA, Wedel MK, et al. (2004) An enema formulation ofalicaforsen, an antisense inhibitor ofintercel-lular adhesion molecule-1 in active ulcerative colitis. Gut 53:1646-1651

Vermeire S, Rutgeerts P (2006) The changing face oftreatment for Crohn's disease. Br J Surg 93:385-386 Wehkamp J, Harder J, Weichenthal M, et al. (2004) NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 53: 1658-1664

Youdim A, Vasikiauskas EA, Targan SR, et al. (2004) A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 10:333-338 Zhou H, Buckwalter M, Boni J, et al. (2004) Population-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis. Int J Clin Pharmacol Ther 42:267-276

Was this article helpful?

0 0
Natural Arthritis Pain Remedies

Natural Arthritis Pain Remedies

It's time for a change. Finally A Way to Get Pain Relief for Your Arthritis Without Possibly Risking Your Health in the Process. You may not be aware of this, but taking prescription drugs to get relief for your Arthritis Pain is not the only solution. There are alternative pain relief treatments available.

Get My Free Ebook


Post a comment